BPC-157 and Cancer Risk: What the 2025 Research Debate Says

TL;DR: The honest answer on BPC-157 cancer risk is that it is unresolved, not settled in either direction. A 2025 review by Józwiak and colleagues flagged BPC-157’s pro-angiogenic, nitric-oxide-driven mechanism as a theoretical hazard in anyone with undiagnosed cancer cells; Sikiric and colleagues, the researchers behind most of the underlying BPC-157 literature, published a pointed rebuttal arguing the peptide behaves as a context-dependent modulator rather than a blanket tumor-feeding driver. Neither side has human tumor-incidence data. This is a live academic dispute about mechanism and interpretation, not a resolved safety question.

If you have spent any time reading about what BPC-157 is, you already know its reputation rests on healing: tendons, gut lining, muscle, nerve. That healing effect runs partly through angiogenesis, the growth of new blood vessels. In 2025, that same mechanism became the center of a genuine academic argument in the journal Pharmaceuticals, playing out across three linked publications. This piece walks through what each side actually said, in their own words.

Why the question exists: angiogenesis is a double-edged mechanism

Angiogenesis is the process of building new blood vessels from existing ones. It is essential to wound healing — a healing tendon or ulcerated gut lining needs new capillaries to feed rebuilding tissue. It is also one of the mechanisms tumors depend on to grow past a few millimeters. A tumor without its own blood supply stays small and starved; one that recruits vasculature can expand and, in some cases, spread. This is the “Folkman model” oncology has worked from for decades: cut the blood supply, and you slow the tumor.

BPC-157’s healing signal runs partly through the same biological pipes tumors exploit. In rodent studies it upregulates VEGFR-2 (a receptor that responds to vascular endothelial growth factor) and stimulates the nitric-oxide system via eNOS, the endothelial nitric oxide synthase enzyme — both established drivers of new-vessel formation. VEGF signaling shows up in a large share of human cancers, including melanoma, ovarian, and thyroid cancer, per the literature Józwiak and colleagues cite. That overlap is the entire basis of the concern: a molecule that reliably switches on VEGFR-2 and eNOS is switching on a pathway malignant cells are also, separately, good at hijacking.

None of that proves BPC-157 causes or accelerates cancer. It establishes why the question is reasonable to ask rather than a fringe worry — which is the position Józwiak and colleagues actually took.

The 2025 exchange: review, rebuttal, reply

This is not a scattered collection of blog posts arguing past each other — it is a formal, three-part exchange inside a single peer-reviewed journal.

That sequence is what a working scientific dispute looks like — not consensus, not a hit piece, but two groups checking each other’s interpretation of the same molecule in public.

Józwiak et al.: the concern, in their words

The original review is broader than the cancer question — it is a full literature and patent survey — but its “Angiogenesis Consequences” section states the concern plainly: “the use of BPC 157 may not be the right choice, especially in situations where we are not aware of the presence of cancer cells in our body.” The logic is straightforward rather than alarmist: stimulated vascular growth can produce abnormal, disorganized vasculature, and abnormal vasculature is exactly the kind of environment that helps tumors resist elimination and grow.

The same review is candid about how thin the human evidence is generally: its section on BPC-157 in humans notes that the peptide “has not been prescribed as a drug,” remains available mostly through unregulated channels, that human studies “are scarce,” and that a 2015 Phase I safety trial was cancelled before results were published. The authors are not claiming BPC-157 causes cancer. They are claiming that a compound with this angiogenic signature, used long-term by people who by definition don’t know their own cancer status, deserves caution rather than an assumption of safety — because nobody has tested that scenario.

Sikiric et al.: the rebuttal, in their words

The rebuttal, from the research group most responsible for the underlying BPC-157 literature, does not concede the point. Their central argument: BPC-157’s relationship to angiogenesis is not the blanket, one-directional process Józwiak’s framing implies. They write that BPC-157 therapy “operates outside the framework of the negative aspects of Folkman’s classical angiogenesis model” and argue it “may counteract the very mechanisms and pathways that contribute to harmful angiogenesis,” rather than simply amplifying vessel growth everywhere it acts. Their nitric-oxide argument follows the same logic: BPC-157’s effect on NO and eNOS activity is described as inseparable from “the counteraction of free radicals formation,” and reported to “strongly oppose the NO-over-release induced by L-arginine” — a homeostatic, balancing action rather than a one-way stimulant push.

On the tumor question specifically, they cite preclinical findings presented as reassuring: BPC-157 “considerably reduced the number of lung metastases induced by melanoma B-16” in mice, counteracted cachexia and prolonged survival in a C26 colon adenocarcinoma model, and — in a single 2004 experiment — showed “a particular anti-tumor effect in the human melanoma cell line.” They also cite corneal neovascularization studies where BPC-157 suppressed abnormal vessel growth, as evidence it can inhibit pathological angiogenesis rather than only feed it. On human data, they counter the scarcity framing by citing a double-blind Phase II ulcerative colitis trial and smaller studies in knee pain and interstitial cystitis, plus rodent toxicology in which no lethal dose was reached.

Józwiak’s reply: holding the line

The reply is where the dispute sharpens rather than resolves. Józwiak and colleagues reject the “modulator, not driver” framing as sufficient, arguing that “scientific integrity requires that arguments be based on a comprehensive and balanced body of data — rather than on selectively chosen fragments.” They call the melanoma cell-line finding “a single… experiment from 2004 (unreplicated),” and “insufficient to support anticancer claims.” They also note that a large majority of published BPC-157 literature traces back to Sikiric’s own group, bearing on how much independent weight any of these findings — reassuring or alarming — should carry. Their bottom line: “no published in vivo data demonstrate that BPC 157 inhibits tumor progression, reduces tumor volume, or suppresses metastasis” to a standard that would settle the question. The tone stays civil — they acknowledge “the Authors’ passion and long-standing work with BPC 157” — but they do not walk the concern back.

What we actually know versus what remains open

It is worth being precise about what “pro-angiogenic” does and does not mean, because this is where forum anxiety tends to get ahead of the evidence. “BPC-157 promotes new blood vessels in a healing tendon” and “BPC-157 feeds a tumor” are different claims, and demonstrating the first does not demonstrate the second. Wound angiogenesis is confined to a site of injury and typically resolves once healing completes; tumor angiogenesis is sustained by the tumor itself, indefinitely, as a survival strategy. A peptide that turns on VEGFR-2 in an injured Achilles tendon is not thereby proven to turn it on inside an undetected mass — that link is theoretical, argued from shared mechanism, not measured directly in animals or people. Sikiric’s group argues the peptide’s actual behavior is more selective than a shared-pathway argument implies; Józwiak’s group argues that until that selectivity is demonstrated independently in a tumor-bearing human, the concern stands. Both are defensible readings of an incomplete dataset — exactly why this remains a live dispute rather than a settled footnote.

For the broader safety picture, our rundown of BPC-157’s timeline and reported side effects covers what gets reported outside this specific debate. If you are comparing BPC-157 to other healing-focused peptides, see our BPC-157 vs. TB-500 comparison; for how the two are discussed together in practice, our guide to common peptide stacks and the BPC-157/TB-500 dosing protocol reference page cover how the pairing is typically framed in the literature and forums.

Frequently asked questions

Does BPC-157 cause tumors?

There is no evidence, in humans or animals, that BPC-157 causes tumors to form. The concern raised by Józwiak and colleagues is different and narrower: that its pro-angiogenic mechanism could theoretically help an already-existing but undetected tumor grow faster, not that the peptide initiates cancer on its own. That theoretical concern has not been tested directly in either direction.

Is BPC-157’s angiogenesis safety actually established?

No, and that is true whether you read the review or the rebuttal. Józwiak and colleagues argue the VEGFR-2/eNOS mechanism is a plausible hazard in undiagnosed malignancy. Sikiric and colleagues argue the peptide acts as a selective, homeostatic modulator rather than a blanket driver of harmful angiogenesis, citing preclinical anti-tumor findings. Both positions rest on rodent and cell-line data; neither has a human safety trial behind it.

Is BPC-157 safe long term?

Long-term human safety has not been established for BPC-157 in general, independent of the cancer-angiogenesis question specifically. The one Phase I human safety trial on record was registered and then cancelled before results were published, and the majority of the supportive literature comes from a single research group, which limits how much independent replication exists either way.

What is the Józwiak-Sikiric debate about BPC-157?

It is a formal three-part exchange in the journal Pharmaceuticals during 2025: a literature review by Józwiak and colleagues raised the theoretical cancer-risk concern tied to BPC-157’s angiogenic mechanism, Sikiric and colleagues published a rebuttal defending the peptide as a selective modulator with some anti-tumor preclinical evidence, and Józwiak and colleagues published a reply maintaining their original concern and questioning the strength and independence of the rebuttal’s evidence.

Does pro-angiogenic activity in a healing wound mean BPC-157 could feed a tumor?

Not necessarily, and that gap is the crux of the whole dispute. Wound angiogenesis is localized and self-limiting; tumor angiogenesis is sustained indefinitely by the tumor as a survival mechanism. Sharing a molecular pathway (VEGFR-2, eNOS) does not automatically mean the same outcome occurs in both settings, but no study has directly measured whether BPC-157 behaves the same way in tumor-bearing tissue as it does in an injured tendon.

References

1. Józwiak M, et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review. Pharmaceuticals. 2025;18(2):185.
2. Sikiric P, et al. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide’s Cytotoxic and Damaging Actions… Comment on Józwiak et al. Pharmaceuticals 2025, 18, 185. Pharmaceuticals. 2025;18(10):1450.
3. Józwiak M, et al. Reply to Sikiric et al. Comment on “Józwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review. Pharmaceuticals 2025, 18, 185.” Pharmaceuticals. 2025.

This article is for research and educational purposes only; BPC-157 is a research-use-only compound and nothing here is medical advice or a human-dosing recommendation.